Exciting industry programs return this year in New Orleans!
There are even more opportunities to learn.
Industry Non-CME (INC) Programs are returning for the 2023 AAD Annual Meeting in New Orleans. Be sure to attend these exciting programs on Thursday, March 16, to Monday, March 20, after the scientific sessions. View full program details and preregister here.
Thursday, March 16:
Advancing Therapeutic Conversations
Presented by: AbbVie
A Practical and Comprehensive Assessment of Alopecia Areata in the Clinic
Presented by: Pfizer, Inc.
Moving Beyond Off-Label Management in Prurigo Nodularis: Looking Toward New Treatment Options
Presented by: PeerView Live
Supported by: an independent educational grant from Sanofi and Regeneron Pharmaceuticals
Friday, March 17:
Join Us to Learn More About SOTYKTUTM (deucravacitinib): Clinical Trial Data and Mechanism of Action
Presented by: Bristol Myers Squibb
Prurigo Nodularis and Atopic Dermatitis: Distinct Diseases with Shared and Unique Roles for Type 2 Inflammation
Presented by: Sanofi and Regeneron
Optimal Treatment of Hidradenitis Suppurativa
Presented by: Novartis
Saturday, March 18:
Caring for All Colors: Embracing Diverse Skin Tones to Advance Research and Patient Management
Presented by: Janssen Scientific Affairs, LLC
More Than Skin-Deep Solutions: The Role of Oral JAK Inhibitors in the Treatment of Atopic Dermatitis
Presented by: Answers in CME
This activity is supported by an educational grant from AbbVie.
Starting Emollient Use in the First Days after Birth in Infants at Risk for Atopic Dermatitis: What Does the Latest Research Tell Us?
Presented by: Johnson & Johnson Consumer, Inc.
Sunday, March 19:
Moderate-to-Severe Atopic Dermatitis: A Deeper Look at Systemic Therapies
Presented by: Med Learning Group
This program is supported by an independent medical educational grant from Sanofi and Regeneron Pharmaceuticals.
Exploring Neoadjuvant Immunotherapies for Surgically Resectable Cutaneous Squamous Cell Carcinoma: Targeting Early Intervention to Achieve Best Outcomes
Presented by: Answers in CME
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
The Next Step in GPP Management: Following the IL-36 Pathway in Generalized Pustular Psoriasis (GPP)
Presented by: Boehringer Ingelheim Pharmaceuticals, Inc.
Monday, March 20:
Reframing the Management Approach for Moderate to Severe Atopic Dermatitis
Presented by: Medscape, LLC.
Supported by an independent educational grant from Lilly.
INC Program content is developed and delivered by the sponsor, independent of the official AAD Meeting planned by its Scientific Assembly Committee and does not qualify for continuing medical education (CME) credit.
Visit AAD DermWorld Meeting News Central for more articles.
